Gilead Sciences, Inc. (NASDAQ:GILD) Position Boosted by Kovack Advisors Inc.

Kovack Advisors Inc. raised its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,495 shares of the biopharmaceutical company’s stock after acquiring an additional 685 shares during the quarter. Kovack Advisors Inc.’s holdings in Gilead Sciences were worth $850,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the company. Nilsine Partners LLC lifted its stake in shares of Gilead Sciences by 1.1% during the third quarter. Nilsine Partners LLC now owns 11,894 shares of the biopharmaceutical company’s stock valued at $891,000 after acquiring an additional 127 shares during the period. Etesian Wealth Advisors Inc. lifted its stake in shares of Gilead Sciences by 0.7% during the fourth quarter. Etesian Wealth Advisors Inc. now owns 18,318 shares of the biopharmaceutical company’s stock valued at $1,486,000 after acquiring an additional 128 shares during the period. Financial Counselors Inc. lifted its stake in shares of Gilead Sciences by 1.5% during the fourth quarter. Financial Counselors Inc. now owns 8,862 shares of the biopharmaceutical company’s stock valued at $718,000 after acquiring an additional 128 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Gilead Sciences by 3.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 3,607 shares of the biopharmaceutical company’s stock valued at $292,000 after acquiring an additional 130 shares during the period. Finally, Institutional & Family Asset Management LLC lifted its stake in shares of Gilead Sciences by 10.3% during the third quarter. Institutional & Family Asset Management LLC now owns 1,501 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 140 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.2 %

NASDAQ GILD opened at $65.42 on Friday. The firm has a market cap of $81.45 billion, a P/E ratio of 181.72, a P/E/G ratio of 1.17 and a beta of 0.19. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The stock’s 50-day moving average is $71.28 and its 200-day moving average is $76.25. Gilead Sciences, Inc. has a one year low of $64.63 and a one year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.49) by $0.17. The business had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 23.08% and a net margin of 1.76%. Gilead Sciences’s quarterly revenue was up 5.3% on a year-over-year basis. During the same period last year, the company earned $1.37 earnings per share. Sell-side analysts anticipate that Gilead Sciences, Inc. will post 3.82 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Investors of record on Friday, June 14th will be issued a dividend of $0.77 per share. The ex-dividend date of this dividend is Friday, June 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.71%. Gilead Sciences’s payout ratio is presently 855.56%.

Wall Street Analyst Weigh In

GILD has been the topic of several analyst reports. StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research note on Friday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday. Finally, Truist Financial lowered Gilead Sciences from a “buy” rating to a “hold” rating and cut their target price for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. Eleven research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $83.87.

Insider Buying and Selling

In related news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the transaction, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.